C12N 2502/30
Tumour cells
Official title: tumour cells
C12N2502/30 (Tumour cells) appears on 172 US grants and 423 published applications in this corpus.
Search patents in C12N- Granted patents
- 172
- Published applications
- 423
- Assignees
- 239
- Inventors
- 943
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 4 | 4 |
| 2002 | 7 | 4 |
| 2003 | 4 | 5 |
| 2004 | 2 | 7 |
| 2005 | 4 | 6 |
| 2006 | 1 | 3 |
| 2007 | 0 | 4 |
| 2008 | 1 | 1 |
| 2009 | 2 | 4 |
| 2010 | 5 | 8 |
| 2011 | 1 | 9 |
| 2012 | 6 | 7 |
| 2013 | 4 | 3 |
| 2014 | 6 | 6 |
| 2015 | 4 | 13 |
| 2016 | 3 | 9 |
| 2017 | 8 | 7 |
| 2018 | 5 | 16 |
| 2019 | 6 | 24 |
| 2020 | 11 | 28 |
| 2021 | 9 | 39 |
| 2022 | 8 | 42 |
| 2023 | 10 | 55 |
| 2024 | 15 | 50 |
| 2025 | 15 | 46 |
| 2026 | 19 | 23 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- K562 universal antigen presenting cells and uses thereof15 Sep 2026US 12,734,239 B2Board of Regents, The University of Texas System
- Methods of preparing anti-human papillomavirus antigen T cells11 Aug 2026US 12,702,706 B2The United States of America, as represented by the Secretary, Department of Health and Human Seervices
- Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells7 Jul 2026US 12,674,138 B2NKMAX Co., Ltd.
- Modified K562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production16 Jun 2026US 12,655,391 B2Gene Solutions Joint Stock Company
- Cd4+ cytotoxic t cells and methods of use thereof8 Oct 2026US 2026/0308522 A1Dana-Farber Cancer Institute, Inc.
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
- Delivery devices17 Sep 2026US 2026/0275256 A1The Methodist Hospital System
- Prostate-specific membrane antigen targeted nf-kb p50-deficient immature myeloid cells27 Aug 2026US 2026/0248849 A1The Johns Hopkins University
- Method for selecting nk cell donor source20 Aug 2026US 2026/0242734 A1Encell Co., Ltd.
Most cited
By later US patents
- CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies343US 6,410,319 B1City of Hope · 2002
- Three-dimensional cell and tissue culture system274US 5,032,508 AMarrow-Tech Incorporated · 1991
- Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use242US 5,192,553 ABiocyte Corporation · 1993
- Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood229US 5,004,681 ABiocyte Corporation · 1991
- Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood74US 6,461,645 B1PharmaStem Therapeutics, Inc. · 2002